Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03168035 · ClinicalTrials.gov registry record · Phase 1
Study of NC-4016 in Patients With Advanced Solid Tumors or Lymphoma
A Phase 1 study, sponsored by NanoCarrier Co..
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT03168035: Completed Phase 1 study, sponsored by NanoCarrier Co..
NCT03168035 is a Phase 1 study that has completed, run by NanoCarrier Co.. The registered enrollment target is 34 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (43% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03168035, a Phase 1 study, has completed, sponsored by NanoCarrier Co..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find the highest tolerated dose of NC-4016 that can be given to patients with advanced solid tumors or lymphoma. The safety of the drug will also be studied.
Primary Outcome
MTD defined as the highest dose level at which no more than 1 of 6 dose limiting toxicity (DLT) evaluable patients experience a DLT during Cycle 1 of dosing. DLT determined by NCI CTCAE v4.03, 14 June 2010.
Interventions
- DRUG NC-4016
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2013-11 |
| Est. Completion | 2017-04 |
| Phase | Phase 1 |
What the finished NCT03168035 record still lists
NCT03168035 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (43% lower).
The record links to 0 conditions, and to 1 intervention - of which NC-4016 is the first listed.
NCT03168035 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03168035 about?
NCT03168035 is a clinical study titled "Study of NC-4016 in Patients With Advanced Solid Tumors or Lymphoma". The goal of this clinical research study is to find the highest tolerated dose of NC-4016 that can be given to patients with advanced solid tumors or lymphoma. The safety of the drug will also be studied.
What is the current status of trial NCT03168035?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2013-11. Estimated completion is 2017-04.
What interventions are being tested in trial NCT03168035?
The interventions under investigation include: NC-4016 (DRUG).
Who is sponsoring clinical trial NCT03168035?
This trial is sponsored by NanoCarrier Co., which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03168035's enrollment target sits among peer trials
34 1273rd of 2000 higher than 721 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia